Borna Amir-Kabirian
Charleston, WVNPI 1275107948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.
Across 167 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$545
- Merck$326
- Regeneron Healthcare Solutions, Inc.$303
- Novartis$301
- Pfizer$265
- AbbVie$251
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,02495%
- Education$2255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 22 | $545 |
| Merck | 16 | $326 |
| Regeneron Healthcare Solutions, Inc. | 10 | $303 |
| Novartis | 9 | $301 |
| Pfizer | 16 | $265 |
| AbbVie | 11 | $251 |
| Incyte Corporation | 9 | $216 |
| Bristol Myers Squibb | 7 | $210 |
| Gilead | 4 | $162 |
| Amgen | 2 | $144 |
| Bayer | 7 | $132 |
| Boehringer Ingelheim | 4 | $128 |
| Recordati_rare_diseases_inc. | 1 | $125 |
| Sanofi | 3 | $120 |
| Johnson & Johnson | 4 | $116 |
| Pharmaessentia USA Corporation | 5 | $113 |
| E.r. Squibb & Sons, L.L.C. | 6 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| EMD Serono, Inc. | 2 | $73 |
| Eisai Inc. | 4 | $64 |
| Coherus Oncology, Inc. | 3 | $57 |
| Puma Biotechnology, Inc. | 3 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Syndax Pharmaceuticals, Inc. | 2 | $34 |
| AstraZeneca | 1 | $28 |
| Genmab U.S., Inc. | 1 | $28 |
| Immunocore Limited | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Beigene USA, Inc. | 1 | $20 |
| Sandoz | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISQALI$140
- LIBTAYO$126
- LUMAKRAS$126
- PANHEMATIN$125
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $945 |
| Atorvastatin Calcium | 22 | $239 |
| Gabapentin | 14 | $144 |
| Losartan Potassium | 11 | $88 |
| Amlodipine Besylate | 17 | $35 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.